优化移植前阿米奥达龙治疗,以预防心脏移植后的初级移植功能障碍
Ye In Christopher Kwon1, Michael Keller1, Alan Lai1
1Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
JHLT open
|October 27, 2025
概括
在心脏移植 (HT) 之前停止使用阿米奥达龙可显著降低初级移植功能障碍 (PGD) 的风险. 这种策略优化了结果,而不会影响长期的移植或接受者生存.
科学领域:
- 心脏病学 心脏病学
- 移植医学 移植医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿米奥达龙经常用于等待心脏移植 (HT) 患者的心律不整.
- 移植前使用阿米奥达龙会带来潜在的副作用,影响移植结果.
- 在HT之前停止阿米奥达龙的最佳时间尚未确定.
研究的目的:
- 评估移植前使用阿米奥达龙对初级移植功能障碍 (PGD) 的影响.
- 评估阿米奥达龙停药时间对移植存活率和HT后接受者结局的影响.
- 在HT候选人中确定阿米奥达龙的最佳外科期间管理策略.
主要方法:
- 来自美国器官共享网络注册表的成年初级隔离HT受体的回顾性分析 (2018年10月-2024年12月).
- 根据amiodarone使用情况分类的患者:从未使用过,继续使用到HT,或在HT前5天内停止使用.
- 倾向性得分匹配和生存分析 (Kaplan-Meier,Cox回归) 用于比较结果.
主要成果:
- 持续使用阿米奥达龙显著增加了严重的PGD (4.1%对2.9%),心脏起器植入,透析和住院.
- 在继续和中止组之间没有观察到死亡率或整体移植失败率的显著差异.
- 与继续使用相比,停止使用阿米奥达龙,特别是在HT前5-30天,显著减少了严重的PGD.
结论:
- 在心脏移植之前停止使用阿米奥达龙可显著减少严重的PGD.
- 这种时间策略优化了外科手术期间的结果,而不会影响长期的接受者或移植的生存.
- 考虑停用阿米奥达龙的时间可能会改善结果,特别是在循环死亡后的捐赠接受者.
更多相关视频
08:15Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion
Published on: November 28, 2025
506
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
1.3K
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
278
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
278
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
457
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
457
01:22Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246